Skip to main
TOI

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oncology Institute is experiencing strong financial performance and its evidence-based approach to integrated care delivery, backed by its expanding presence and utilization of technology, positions the company for future growth. Additionally, its Specialty Pharmacy segment generates significant revenue through its payment arrangements. However, competition and high debt remain potential risks to the company's success in the value-based oncology care market. Regardless, TOI is seen as a promising solution to mitigate rising oncology costs and is expected to achieve financial stability in the near future.

Bears say

Oncology Institute is facing a tough market environment with potential challenges from payors struggling with oncology inpatient and Part B spend. While the company has potential for growth with its delegated and capitated contracts, the current market conditions and the company's historically low margins make it difficult to achieve profitability in the short term. The company's high debt levels and potential need for equity financing in the future are also potential concerns for investors.

TOI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TOI has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.